STRICTLY CONFIDENTIAL

Application No:

[For internal IAAF use only]



IAAF Therapeutic Use Exemptions **Abbreviated Application Form ATUE**

Plea	se complete all sections <u>in capital letters or typing</u>
□ beta-2 agonists by inhalation	☐ Glucocorticosteroids by intra-articular injection, intra-bursal injection, peritendinous injection, intra-cystic injection, pulmonary inhalation, iontophoresis or anal topical preparation
	oval for the therapeutic use of a prohibited substance on the IAAF bject to the Abbreviated TUE Application Procedure
☐ I am included in IAAF Registe	red Testing Pool or
Preparing for IAAF Internation	nal Competition (which competition
1. Athlete information	
First Name:	Last Name:
Female	Discipline:
Address:	
City:	Country:
Postal Code:	Date of birth (dd/mm/yy):
Tel.: (with international	code) Mobile:
E-mail:	National Federation:
2. Medical information	
Diagnosis (see Note 1): .	

STRICTLY CONFIDENTIAL

Prohibited substance(s)	Dose of	Route of	Frequency of			
(see Note 1 and 2):	administration	administration	administration			
Commercial name / Generic name						
e.g: Ventolin / Salbutamol or Albuterol						
1.						
2.						
3.						
Intended duration of treatment C	Once only	Emergency	1			
	or duration (week / month					
3. Medical practitioner's and at	hlete's declaration					
I certify that the above-mentioned medication(s) for the above-named athlete has been/is to be administered as the correct treatment for the above-named medical condition. I further certify that the use of alternative medications not on the IAAF Prohibited List would be unsatisfactory for the treatment of the above-named medical condition for the following reasons:						
would be unsatisfactory for the treatment of t		_				
Name, qualifications and medical	speciality (see Note 3	3):				
Address:						
City: State	City:					
Postal Code: E	mail:					
Tel.: (with international code)						
Signature of Medical Practition	e r:	Dat	te:			
I,	bstance in the IAAF Prohibi IAAF Therapeutic Use Exerble, WADA or IOC staffed in the management, review that, if I ever wish to reward medical practitioner in whose the standard practitioner in the standard practitioner in the standard practition in the standard pr	ted List. I authorize, if ne mption Sub-Commission and/or members of the v or administration of my woke the right of the IA iting of the fact. As a control of the sub-control of the su	cessary, the release of my personal (TUESC), as well as to any other WADA or IOC Therapeutic Use application in accordance with the AF TUESC to obtain any health			
I further authorise for the decision of the IA Rule 34.5.	AF TUESC to be notified to	any other relevant organ	nisations in accordance with IAAF			
Athlete's signature:						
Parent's/Guardian's signature: (if the athlete is a minor, a parent or gua						

STRICTLY CONFIDENTIAL





IAAF BETA-2-AGONIST PROTOCOL <u>Medical Records FORM</u>

NAME OF THE ATHLETE:			
DATE OF BIRTH:	OF BIRTH: COUNTRY:		
Diagnosis:			
Age of onset:			
Symptoms spontaneous or exercise relative		ъ	Y Y
Coughing during or post-exercise:	Yes or No Yes or No	Dyspnoea:	Yes or No
Shortness of breath: Chest tightness:	Yes or No	Wheezing: Excess sputum:	Yes or No Yes or No
If yes, specify:	103 01 110	Execss sputum.	Tes of No
Identified triggering factors :			
Past history of atopic disorders and/or o	childhood asthn	ıa:	
Past physical examinations:			
Results of skin prick tests or RAST to d	ocument the pr	esence of allergic hypers	sensitivity:
Details of all consultations with qualified Details of any attendance in hospital etreatment of acute exacerbation of asthropher Details of the individual's currently preyears, with particular details in the last Details of medication in the 3 months presented.	mergency depa na. scribed medica 6 months.	nrtments for treatment	or admission to hospital for
Details of medication in the 3 months pr	nor to provocat	ion test:	
PFTesting information		Date of test	t: /
□ Bronchodilator test: FEV ₁ after bron □ Methacholine challenge test PD ₂₀ = μmol or		nange compared to base	line: %
$PC_{20} = \dots mg/mL$			
☐ Eucapnic Voluntary Hyperpnoea: F	FEV ₁ decrease	of % within .	min
☐ Exercise challenge: FEV₁ decrease	of%	within min	
\square Hypertonic saline test: FEV ₁ decre	ase of	%	
Date: Physician Name:	Phys	sician signature:	

Notes:

Note 1	Diagnosis and Medical examination(s)/test(s) performed For applications for the use of Beta-2-agonists only: To constitute a complete application, International-Level athletes must include the following documentation required by the IAAF Beta-2-Agonists Protocol: 1. Detailed Medical Records
	2. Provocation Test Results
	Both must be filled in on page 3 of this Application Form
	Refer to the IAAF Beta-2 Agonists Protocol www.iaaf.org/antidoping for further more detailed information on the documentation that is required.
Note 2	Medication details / change of prescription
	Provide both the commercial and generic name (INN) of the medication and specify medication dose, the route of administration and the frequency of administration.
	Note that a new TUE application will be required for any change of prescription.
Note 3	Name, qualifications and medical specialty
	For example: Dr AB Cook, MD FRACP, Gastro-enterologist. Dr JA Gonzalez. MBBS, FACSM, Sports Physician

<u>WARNING</u>: Incomplete Applications will be returned and will need to be re-submitted.

Please submit the completed application to the IAAF Medical and Anti-Doping Department (see contact details below) and keep a copy of the Form for your records:

IAAF Medical and Anti-Doping Department

17, Rue Princesse Florestine BP 359 – MC 98007 Monaco

Confidential Fax: +377 93 50 83 95

If there are any questions arising from this Form or regarding the relevant procedures for abbreviated applications for TUEs on an international level, please contact the IAAF for further information on: +377 93 10 88 89 (tel) or tue-application@iaaf.org (e-mail).